Matsumoto, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 (Shiba-Kyoritsu)

Position

Professor

Career 【 Display / hide

  • 2003.04
    -
    2007.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 医療職員

  • 2007.04
    -
    2014.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 主任

  • 2014.04
    -
    2017.03

    慶應義塾大学薬学部, 実務薬学講座, 准教授

  • 2017.04
    -
    Present

    慶應義塾大学薬学部, 薬効解析学講座, 教授

Academic Background 【 Display / hide

  • 1994.04
    -
    1998.03

    Kumamoto University, 薬学部, 薬学科

    University, Graduated

  • 1998.04
    -
    2000.03

    Kumamoto University, 薬学研究科

    Graduate School, Completed, Master's course

  • 2000.04
    -
    2003.03

    Kumamoto University, 薬学研究科

    Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide

  • 博士(薬学), Kumamoto University, Coursework, 2003.03

    α1-酸性糖蛋白質の生理作用と動態特性に関する研究

Licenses and Qualifications 【 Display / hide

  • 薬剤師免許証, 1998.07

  • 日本薬剤師研修センター認定薬剤師, 2006.03

  • 日本医療薬学会認定薬剤師, 2009.01

  • インフェクションコントロールドクター, 2009.01

  • 感染制御専門薬剤師, 2009.03

display all >>

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy

Research Keywords 【 Display / hide

  • Pharmacokinetics/Pharmacodynamics

  • Therapeutic drug monitoring

  • 抗菌化学療法

  • 高齢者医療

Research Themes 【 Display / hide

  • 医薬品の薬効評価と副作用解析に基づいた薬物療法の最適化に関する研究, 

    2014.04
    -
    Present

 

Books 【 Display / hide

  • 今日の治療薬2025

    松元一明, 南江堂, 2025.01

  • 今日の治療指針2025

    松元一明, 医学書院, 2025.01

    Scope: 市中肺炎/急性中耳炎 服薬指導・薬剤情報

  • ベーシック薬学教科書シリーズ 薬物治療学(第2版増補版)

    松元一明, 化学同人, 2024.03

    Scope: 第13章感染症と薬物治療.

  • 外来・薬局感染症学

    松元一明, じほう, 2024.03

    Scope: β-ラクタム系薬.

  • ケースで学ぶ老年薬学

    松元一明, 日経BP, 2024.01

    Scope: 感染症.

display all >>

Papers 【 Display / hide

  • External validation of a flowchart related to achieving the target area under the concentration-time curve for vancomycin: A retrospective multicenter study

    Ishigo T., Suzuki A., Ibe Y., Fujii S., Fukudo M., Yoshida H., Tanaka H., Fujihara H., Yamaguchi F., Ebihara F., Maruyama T., Yagi Y., Hamada Y., Samura M., Nagumo F., Komatsu T., Tomizawa A., Takuma A., Chiba H., Nishi Y., Igarashi Y., Enoki Y., Matsumoto K.

    Journal of Infection and Chemotherapy 31 ( 5 ) 102701 2025.05

    Joint Work,  ISSN  1341321X

     View Summary

    During therapeutic drug monitoring (TDM) for vancomycin (VCM), the area under the concentration-time curve (AUC) is important for balancing efficacy versus toxicity. In a previous study, we developed a decision tree (DT) model to achieve the target AUC during TDM over the follow-up period (AUCfollow-up). This study aimed to validate the DT model for achieving the target AUCfollow-up. Patients who received VCM for at least 72 h and had an initial TDM within four doses between January 2023 and December 2023 were analyzed. The AUC of the initial TDM was calculated over 2-point (peak/trough) concentrations via Bayesian estimation. The target AUCfollow-up was defined as 400–600 μg h/mL. Among 188 patients (median age [interquartile range], 66 [56, 79] years; 50 % female), the target AUCfollow-up was achieved in 70 % (132/188). When the predicted AUC was 400–600 μg h/mL, 84 % (102/121) achieved the target AUCfollow-up. In a 12 h dosing interval subgroup, 86 % (88/102) achieved the target AUCfollow-up. Conversely, when the predicted AUC was <400 or >600 μg h/mL, the proportion who achieved the target AUCfollow-up dropped to 44 % (30/67). Only 30 % (3/10) of those with creatinine clearance rates of >130 mL/min/1.73 m2 achieved the target. The area under the receiver operating characteristics curve was 0.74, and the R2 value was 0.15. Our findings confirmed the external validity of the DT model and supported its use for optimizing VCM dosing. Overall, the DT model offers a reliable framework for achieving target AUC values during follow-up for TDM, aiding safe and effective treatment.

  • Methemoglobin-Encapsulating Liposome: A Low-Risk Intravascular Contrast Agent for Magnetic Resonance Imaging

    Taguchi K., Sumiyoshi A., Suzuki Y., Ozawa Y., Iiyama M., Gao S., Sakai H., Osada K., Matsumoto K., Aoki I.

    ACS Applied Bio Materials 8 ( 4 ) 2838 - 2846 2025.04

    Joint Work

     View Summary

    Hemoglobin shows different contrasts on magnetic resonance imaging (MRI) depending on the iron and oxygenation states of heme. Functional brain MRI utilizes the differences in the concentrations of oxyhemoglobin and deoxyhemoglobin in cerebral blood vessels; blood clots produce strong magnetic susceptibility effects. We hypothesized that methemoglobin (MetHb)-based nanoparticles can act as MRI contrast agents because MetHb levels in red blood cells affect relaxivity and are strictly regulated to <1% in the blood. Herein, we describe the synthesis of methemoglobin-encapsulated liposomes (Met-HbVs) as contrast agents for MRI. Met-HbV, with a size of approximately 200 nm, increased longitudinal relaxivity (r1) by 2.44-fold compared with hemoglobin-encapsulated liposomes in vitro. In contrast, the transverse relaxation capacity (r2) of Met-HbVs was similar to that of the hemoglobin-encapsulated liposomes. Owing to its relaxivity, Met-HbV enhanced the signal intensity on T1-weighted images and angiography, especially in the veins. Furthermore, deleterious biological responses were seldom observed after Met-HbV administration in mice with chronic renal failure. In conclusion, Met-HbV possesses potential as a vascular contrast agent in MRI for angiography, with advantages over gadolinium-based contrast agents in terms of safety for patients with renal failure. To the best of our knowledge, this is the first report demonstrating the potential of MetHb as a biomaterial for contrast agents in MRI.

  • Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system.

    Takada K, Enoki Y, Samura M, Igarashi Y, Taguchi K, Tanikawa K, Matsumoto K

    Expert opinion on drug safety    1 - 7 2025.04

    Joint Work,  ISSN  1474-0338

     View Summary

    Background: Metronidazole (MNZ) can be administered for various infections. The impact of comorbidities/concomitant drugs on MNZ-induced central nervous system (CNS) disorders remains unclear. Research design and methods: We assessed the risk of metronidazole-related CNS disorders using the Japan Adverse Drug Event Report (JADER, May 2023) and the US Food and Drug Administration Adverse Event Reporting System (FAERS, Q1 2023), excluding comorbidities/concomitant drugs. Clonazepam and diazepam were evaluated as potential prophylactics based on the efficacy of benzodiazepines for MNZ-related CNS disorders. Reporting odds ratios (ROR) and 95% confidence intervals (CI) were calculated. Additionally, sensitivity analysis by sex and age was conducted. Results: The ROR (95% CI) of CNS disorders associated with MNZ in JADER and FAERS were 3.16 (2.69–3.72) and 1.69 (1.64–1.73), respectively. MNZ was significantly related to CNS disorders after excluding comorbidities (brain/spinal cord or liver abscesses) and concomitant drugs (glucocorticoids, antiepileptic, antiparkinson, and schizophrenia drugs). In sensitivity analysis, MNZ was significantly related to CNS disorders, despite sex and age. The ROR in the concomitant with clonazepam (CZP) was 0.70 (0.53–0.92) in FAERS. Conclusion: MNZ may be associated with CNS disorders, even if comorbidities/concomitant drugs that are potential risk factors for CNS disorders are excluded. Additionally, CZP may suppress CNS disorders.

  • Direct comparison of the effects of first- and second-generation H(1) -receptor blockers on motor functions in mice.

    Taguchi K, Tenjin K, Sakamoto Y, Shimada A, Hara R, Iketani O, Okamoto Y, Enoki Y, Kizu J, Hori S, Matsumoto K

    Die Pharmazie 80 ( 1 ) 24 - 28 2025.03

    Joint Work,  ISSN  0031-7144

  • Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age.

    Takada K, Samura M, Igarashi Y, Suzuki A, Ishigo T, Fujii S, Ibe Y, Yoshida H, Tanaka H, Ebihara F, Maruyama T, Hamada Y, Komatsu T, Tomizawa A, Takuma A, Chiba H, Yagi Y, Nishi Y, Enoki Y, Taguchi K, Tanikawa K, Kunishima H, Matsumoto K

    Journal of pharmaceutical health care and sciences 11 ( 1 ) 18 2025.03

    Joint Work,  ISSN  2055-0294

     View Summary

    Background: Population pharmacokinetic (PPK) models of vancomycin (VCM) commonly use creatinine clearance (CLcr) as a covariate for clearance (CL). However, relying on CLcr in patients of advanced age may lead to inaccuracies in estimating VCM clearance. Therefore, this study aimed to develop and validate a new PPK model specifically for patients aged 75 years and older. Methods: PPK analysis was performed based on the blood concentrations of VCM (n = 159 patients). The predictive performance of the developed model was compared with that of previous models using mean absolute error (MAE) and mean squared error (MSE) for another dataset. Results: The PPK analysis optimized a two-compartment model using CLcr and the Alb levels as covariates at the central compartment of VCM clearance. The final model was as follows: CL (L/h) = 1.96 × (CLcr/3.09) 0.63 × (Serum albumin (Alb) /2.3) 0.22 × exponential (0.11). Clearance between the central and peripheral compartments (L/h) = 4.86. Central compartment volume of distribution (L) = 31.78. Peripheral compartment volume of distribution (L) = 53.64. The validation study revealed that compared with those of previous models (ranging from 0.67 to 0.79 L/h and from 0.81 to 1.11 (L/h)2, respectively), the final model demonstrated the smallest MAE of 0.60 L/h and MSE of 0.65 (L/h)2 for patients of advanced age with serum creatinine levels of < 0.6 mg/dL. Conclusion: The PPK model of VCM for patients of advanced age was optimized by adding the Alb levels and CLcr as covariates for CL. The predictive accuracy of the PPK model for patients with an SCr of < 0.6 mg/dL tended to be higher than those of previous models based just on CLcr. Thus, dosage is suggested to be adjusted based on CLcr and Alb levels for patients with an SCr of < 0.6 mg/dL.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • Reply to Mitsuboshi, “Enhancing result reliability by addressing potential confounding factors”

    Ishigo T., Matsumoto K., Yoshida H., Tanaka H., Ibe Y., Fujii S., Fukudo M., Fujihara H., Yamaguchi F., Ebihara F., Maruyama T., Hamada Y., Samura M., Nagumo F., Komatsu T., Tomizawa A., Takuma A., Chiba H., Nishi Y., Enoki Y., Taguchi K., Suzuki A.

    Microbiology Spectrum 13 ( 3 ) e0149924 2025.03

  • 抗微生物薬適正使用支援プログラム実践のためのガイダンス

    川口 辰哉, 賀来 満夫, 青木 洋介, 小阪 直史, 関 雅文, 田邊 嘉也, 藤田 直久, 前田 真之, 村木 優一, 森田 邦彦, 柳原 克紀, 山田 武宏, 吉田 耕一郎, 二木 芳人, 柳原 克紀, 関 雅文, 菅野 みゆき, 菅原 えりさ, 清祐 麻紀子, 高橋 俊司, 山本 剛, 森田 邦彦, 松元 一明, 村木 優一, 池田 賢二, 篠原 孝幸, 山岸 由佳, 公益社団法人日本化学療法学会・一般社団法人日本感染症学会・一般社団法人日本環境感染学会・一般社団法人日本臨床微生物学会・公益社団法人日本薬学会・一般社団法人日本医療薬学会・一般社団法人日本TDM学会・一般社団法人日本医真菌学会8学会合同抗微生物薬適正使用推進検討委員会

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  73 ( 2 ) 95 - 156 2025.03

    ISSN  1340-7007

  • 小児消化管感染症診療ガイドライン2024

    日本小児感染症学会/日本小児消化管感染症・免疫アレルギー研究会

     2024.11

  • MRSA感染症の診療ガイドライン2024

    光武 耕太郎, 松本 哲哉, 植田 貴史, 内山 勝文, 小澤 俊幸, 唐牛 春香, 菅井 基行, 関 雅文, 高橋 聡, 竹末 芳生, 中嶋 一彦, 中嶋 秀人, 中南 秀将, 畑 啓昭, 藤倉 雄二, 藤村 茂, 松下 和彦, 松元 一明, 三鴨 廣繁, 宮入 烈, 柳原 克紀, 山岸 由佳, 山口 哲央, 山田 浩司, 山本 善裕, 吉田 耕一郎, 池田 信介, 岩田 栄一朗, 大野 久美子, 大野 智裕, 加勢田 富士子, 加藤 秀雄, 加茂野 絵美, 川崎 洋平, 川筋 仁史, 小林 直実, 坂 なつみ, 瀬戸 良教, 高野 昇太郎, 浜田 幸宏, 松本 浩, 荒川 創一, 岩田 敏, 金光 敬二, 公益社団法人日本化学療法学会, 一般社団法人日本感染症学会MRSA感染症の診療ガイドライン作成委員会

    日本化学療法学会雑誌 ((公社)日本化学療法学会)  72 ( 3 ) 251 - 321 2024.05

    ISSN  1340-7007

  • 呼吸器及び尿路感染症におけるブレイクポイント 新規抗菌薬の追加(2023)

    平松 和史, 青木 弘太郎, 荒岡 秀樹, 猪川 和朗, 石井 良和, 大塚 喜人, 大谷 真理子, 柴山 恵吾, 舘田 一博, 松永 直久, 松元 一明, 冨山 直樹, 三学会合同ブレイクポイント臨床応用検討委員会, 日本化学療法学会, 日本感染症学会, 日本臨床微生物学会

    日本臨床微生物学会雑誌 ((一社)日本臨床微生物学会)  33 ( 4 ) 253 - 254 2023.09

    ISSN  2434-866X

display all >>

Presentations 【 Display / hide

  • 抗菌薬曝露時におけるMycobacterium abscessusのコロニー形態変化.

    島村莉奈、西村知泰、三澤可奈、吉川万衣子、柏村祥子、矢野大和、矢野郁也、榎木裕紀、田口和明、松元一明、長谷川直樹.

    第55回結核・非定型抗酸菌症治療研究会 (東京都) , 

    2024.11

    Oral presentation (general)

  • Mycobacterium aviumとMycobacterium intracellulareの臨床分離株を用いたβ-ラクタム系抗菌薬2剤併用の有効性評価.

    吉川万衣子、西村知泰、三澤可奈、島村莉奈、鈴木健太、柏村祥子、榎木裕紀、田口和明、松元一明、長谷川直樹.

    第55回結核・非定型抗酸菌症治療研究会 (東京都) , 

    2024.11

    Oral presentation (general)

  • 非発熱時または発熱時におけるニューキノロン系抗菌薬の体温低下.

    原量平、榎木裕紀、田口和明、松元一明.

    第34回日本医療薬学会年会 (千葉県) , 

    2024.11

    Oral presentation (general)

  • 日本医療薬学会賞・学術賞・奨励賞受賞講演:抗感染症薬の個別最適化を目指した基礎・臨床研究

    松元一明.

    第34回日本医療薬学会年会 (千葉県) , 

    2024.11

    Public lecture, seminar, tutorial, course, or other speech

  • Clostridioides difficileに対する標準治療薬2剤併用の有効性評価.

    池上眞太郎、田代渉、榎木裕紀、田口和明、松元一明.

    第34回日本医療薬学会年会 (千葉県) , 

    2024.11

    Oral presentation (general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 新規肺MABC症治療薬の開発と革新的非臨床PK/PD評価法の構築

    2024.04
    -
    2028.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • 薬剤耐性淋菌・緑膿菌に有効な新規抗菌剤の開発

    2023.08
    -
    2024.03

    国立研究開発法人日本医療研究開発機構(AMED), 新興・再興感染症に対する革新的医薬品等開発推進研究事業, Joint research, Coinvestigator(s)

  • ホローファイバー感染モデルを用いたカルバペネム耐性菌感染症の抗菌薬併用療法に関する橋渡し研究

    2022.04
    -
    2025.03

    国立研究開発法人国立国際医療研究センター, 国際医療研究開発事業, Joint research, Coinvestigator(s)

  • マウス肺感染モデルを用いたOP0595の臨床有効性予測

    2022.01
    -
    2024.03

    Meiji Seikaファルマ株式会社, Commissioned research, Principal investigator

  • Investigation of the effectiveness of imeglimin as a potential therapeutic agent for sarcopenia

    2021.09
    -
    2023.08

    大日本住友製薬株式会社, Commissioned research, Principal investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Date applied: 特願2020-144044  2020.08 

    Patent, Joint

Awards 【 Display / hide

  • 2024年度日本医療薬学会学術賞

    松元一明., 2024.11, 抗感染症薬の個別最適化を目指した基礎・臨床研究.

  • 第36回微生物シンポジウム優秀発表賞(ポスター発表)

    林侑孝、髙橋実秀、佐々木萌、劉小茜、榎木裕紀、田口和明、松元一明., 2024.08, In vivoおよびIn vitro感染モデルを用いた腸球菌感染症に対するバンコマイシンのPK/PD評価.

  • MRSAフォーラム2024一般演題優秀賞

    高橋実秀、佐々木萌、劉小茜、林侑孝、榎木裕紀、田口和明、松元一明., 2024.07, In vivo実験から得られた腸球菌感染症に対するバンコマイシンの目標PK/PDパラメータ値.

  • 第7回フレッシャーズ・カンファランス優秀演題発表賞

    三原貴之、田口和明、榎木裕紀、松元一明., 2024.06, デキストラン硫酸ナトリウム誘発性炎症性腸疾患マウスモデルにおけるfidaxomicinの抗炎症効果の評価と腸内細菌叢の解析.

  • 第44回日本臨床薬理学会学術総会優秀発表賞

    並木孝哉、横山雄太、枦秀樹、織田錬太郎、地引綾、河添仁、松元一明、鈴木小夜、中村智徳., 2023.12, 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築.

display all >>

 

Courses Taught 【 Display / hide

  • CLINICAL PHARMACOLOGY AND PHARMACEUTICS

    2025

  • CLINICAL PHARMACOLOGY

    2025

  • BACHELOR'S THESIS

    2025

  • ADVANCED DRUG INFORMATICS

    2025

  • DOCTORAL LECTURE ON CLINICAL PHARMACY 1

    2025

display all >>

 

Social Activities 【 Display / hide

Memberships in Academic Societies 【 Display / hide

  • 日本医真菌学会, 

    2019.02
    -
    Present
  • 日本DDS学会, 

    2018.05
    -
    Present
  • 日本臨床微生物学会, 

    2018.03
    -
    Present
  • 日本老年薬学会 理事・評議員, 

    2016.04
    -
    Present
  • 日本薬剤学会 代議員, 

    2015.12
    -
    Present

display all >>